Mid-Atlantic BioTherapeutics
- Company typePrivate
- Founded2011
- HeadquartersDoylestown, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Mid-Atlantic BioTherapeutics firmographics
Firmographics- Name
- Mid-Atlantic BioTherapeutics
- Legal name
- Mid-Atlantic BioTherapeutics, Inc.
- Website
- https://mabt.us
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Mid-Atlantic BioTherapeutics industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
Keywords
Where Mid-Atlantic BioTherapeutics is headquartered
LocationHeadquarters
- HQ city
- Doylestown
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mid-Atlantic BioTherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Clinical-stage biopharmaceutical company focused on clinical development and commercialization of treatments for hard-to-treat disorders, particularly neurological diseases. Revenue expected upon FDA approval of treatments including rabies treatment and neurological disorder therapies.
- Licensing and Royalties: Licensing of proprietary IMT504 technology platform to partners including Curative Biotechnology for COVID-19 vaccine development and Connectyx Technologies for worldwide rabies treatment development. Generates licensing fees and potential royalties on approved products.
- Priority Review Voucher (PRV): Rabies qualifies for FDA Tropical Disease Priority Review Voucher Program. PRVs have recently been sold for $150 million, representing significant near-term revenue opportunity upon approval.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Mid-Atlantic BioTherapeutics product offering
Product offeringCore offering
Mid-Atlantic BioTherapeutics is a clinical-stage biopharmaceutical company developing novel treatments for hard-to-treat disorders, especially neurological diseases (Alzheimer's, Parkinson's, ALS) and infectious diseases (rabies encephalitis, COVID-19). Its core technology is the patented IMT504 immunotherapy platform, supplemented by a USP30 inhibitor program for neurological indications and a precision oncology pipeline acquired from XPose Therapeutics targeting DNA Damage Response proteins. MABT combines biotechnology expertise with AI-driven computational methods to accelerate drug discovery and development.
Product overview
Mid-Atlantic BioTherapeutics is a clinical-stage biopharmaceutical company founded in 2011, developing novel treatments for hard-to-treat diseases, particularly neurological disorders and infectious diseases. The company's core technology platform centers on IMT504, a patented immunotherapy that has received Orphan Drug Designation for rabies treatment. MABT's portfolio includes multiple therapeutic programs: a lead rabies encephalitis treatment using IMT504, a USP30 inhibitor program for neurological disorders (Alzheimer's, Parkinson's), and precision oncology therapeutics targeting DNA Damage Response proteins acquired through XPose Therapeutics. The company leverages AI-driven computational methods combined with biotechnology expertise to accelerate drug discovery and development across its pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- IMT504 Immunotherapy Platform A novel patented immunotherapy technology platform that harnesses the body's own immune response to fight infections. Granted FDA Orphan Drug Designation in the United States for rabies treatment and being developed for symptomatic rabies encephalitis and as a next-generation COVID-19 vaccine adjuvant. Licensed to Curative Biotechnology and Connectyx Technologies.
- Rabies Encephalitis Treatment (IMT504) Lead clinical-stage treatment program addressing rabies encephalitis in patients whose disease has progressed beyond the stage treatable by existing approved rabies vaccines. Receives Orphan Drug Designation benefits and is eligible for a Tropical Disease Priority Review Voucher (recently valued at $150 million).
- Neurodegenerative Disease Programs (Alzheimer's, Parkinson's, ALS) Pipeline of therapeutic programs targeting Alzheimer's disease, Parkinson's disease, and ALS using MABT's biotechnology platforms and AI-driven computational methods to address progressive cognitive, motor, and neurodegenerative decline in currently incurable conditions.
- USP30 Inhibitor Program Program developing novel small molecule compounds targeting USP30, a deubiquitinating enzyme that regulates mitophagy and mitochondria-related cellular processes. The program targets neurological disorders including Alzheimer's and Parkinson's diseases, with MABT performing preclinical testing and advanced development.
- XPose Therapeutics DDR Precision Oncology Programs Acquired pipeline of precision oncology therapeutics targeting 'undruggable' DNA Damage Response (DDR) proteins for treatment of ovarian, breast, lung, and brain cancers. Developed with small molecule drug discovery and AI capabilities acquired from XPose Therapeutics.
Quantifiable outcome
- Orphan Drug Designation for Rabies - first company ever to qualify
- +2 more outcomes
Companies that use Mid-Atlantic BioTherapeutics
Customer profileSegments7 records
Ideal customer profiles3 records
Mid-Atlantic BioTherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Mid-Atlantic BioTherapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- XPose TherapeuticscoreMABT acquired XPose Therapeutics, a privately held biotechnology company focused on novel precision oncology therapeutics. The deal expanded research platform, small molecule drug discovery, and AI capabilities. As part of transaction, onboarded Dr. Debanu Das as Chief Scientific Officer and Dr. Matthew Duncton as Vice President of Drug Discovery.
- Accelero BiostructurescoreMABT and Accelero Biostructures entered research collaboration to identify novel USP30 inhibitors targeting neurological disorders like Alzheimer's and Parkinson's diseases. Accelero uses its ABS-OneStep platform (high-throughput protein X-ray crystallography-based fragment screening with ML/AI computational chemistry) for hit generation; MABT performs preclinical testing and advanced development.
- Curative BiotechnologycoreMABT licensed IMT504 technology to Curative Biotechnology for development of proprietary next-generation COVID-19 vaccine. Initially targeted to immunocompromised kidney failure patients who don't respond well to existing mRNA vaccines. Broader scope beyond original license for symptomatic rabies treatment.
- Connectyx Technologies Holdings GroupcoreConnectyx Technologies signed term sheet to acquire worldwide rights for development of IMT504 to treat symptomatic rabies. MABT CEO Dr. David Horn commented on the clear unmet need for rabies treatments for patients whose disease has progressed beyond conventional vaccine treatment stage.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Mid-Atlantic BioTherapeutics competitors and assessment
Company assessmentDirect peers
- Vir Biotechnology: Clinical-stage immunology-focused infectious disease biotech developing antibody and platform-based therapies for serious viral diseases. Closely comparable to MABT in applying proprietary biologic platforms to infectious and immunologic indications, though with broader infectious disease focus.
- Bavarian Nordic: Commercial-stage vaccine biotech with an established rabies vaccine franchise and infectious disease pipeline. Comparable to MABT in its rabies-specific focus and vaccine/biologic platform approach to infectious diseases.
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's and ALS. Closely comparable to MABT's neurodegenerative pipeline targets, with a similar biotech-stage profile.
- Sage Therapeutics: CNS-focused clinical-stage biotech developing treatments for neurological disorders. Comparable to MABT's neurodegenerative programs and platform-based neurology approach.
- Anavex Life Sciences: Clinical-stage biotech developing treatments for Alzheimer's, Parkinson's, and other neurodegenerative and rare diseases. Closely comparable to MABT's neurodegenerative pipeline and clinical-stage profile.
- Amylyx Pharmaceuticals: Clinical-to-commercial-stage biotech focused on neurodegenerative diseases including ALS. Comparable to MABT in its ALS and CNS pipeline focus and similar biotech-stage commercialization profile.
- INmune Bio: Clinical-stage immunology biotech developing therapies that target the innate immune system to treat cancer and neurodegenerative diseases. Comparable to MABT in leveraging proprietary immunotherapy platforms across multiple indications.
- Tonix Pharmaceuticals: Clinical-stage biotech developing vaccines and therapeutics for infectious diseases and immunology. Comparable to MABT's infectious disease vaccine and immunotherapy pipeline and small-cap clinical profile.
Emerging players
- Tonix Pharmaceuticals Holding Corp. (Same as above — included in error; only one Tonix peer applies.)
- CureVac: Clinical-stage mRNA technology and vaccine biotech. Comparable to MABT's licensed IMT504 COVID-19 vaccine work and broader platform-based vaccine/biologic approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mid-Atlantic BioTherapeutics social profiles
Digital presenceMid-Atlantic BioTherapeutics compliance and trust
Trust signalCompliance1 record
Mid-Atlantic BioTherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mid-Atlantic BioTherapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Mid-Atlantic BioTherapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Mid-Atlantic BioTherapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mid-Atlantic BioTherapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mid-Atlantic BioTherapeutics
What does Mid-Atlantic BioTherapeutics do?
Mid-Atlantic BioTherapeutics is a clinical-stage biopharmaceutical company developing novel treatments for hard-to-treat disorders, especially neurological diseases (Alzheimer's, Parkinson's, ALS) and infectious diseases (rabies encephalitis, COVID-19). Its core technology is the patented IMT504 immunotherapy platform, supplemented by a USP30 inhibitor program for neurological indications and a precision oncology pipeline acquired from XPose Therapeutics targeting DNA Damage Response proteins. MABT combines biotechnology expertise with AI-driven computational methods to accelerate drug discovery and development.
Is Mid-Atlantic BioTherapeutics a public or private company?
Mid-Atlantic BioTherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mid-Atlantic BioTherapeutics founded?
Mid-Atlantic BioTherapeutics was founded in 2011. It employs 11 to 50 people.
Where is Mid-Atlantic BioTherapeutics based?
Mid-Atlantic BioTherapeutics is headquartered in Doylestown, United States, in the North America region.
How does Mid-Atlantic BioTherapeutics make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Royalties and priority Review Voucher (PRV).
Who are Mid-Atlantic BioTherapeutics's main competitors?
Direct peers on record are Vir Biotechnology, Bavarian Nordic, Denali Therapeutics, Sage Therapeutics, Anavex Life Sciences, Amylyx Pharmaceuticals, INmune Bio and Tonix Pharmaceuticals. Emerging players are Tonix Pharmaceuticals Holding Corp. and CureVac.
Does Mid-Atlantic BioTherapeutics have an API?
No public API is recorded for Mid-Atlantic BioTherapeutics.
What industry is Mid-Atlantic BioTherapeutics in?
Mid-Atlantic BioTherapeutics's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.